BioSight
Companies
Opus Genetics, Inc. logo

IRD

NASDAQDURHAM, NC
Opus Genetics, Inc.

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company developing adeno-associated virus-based gene therapies for inherited retinal diseases including Leber congenital amaurosis, bestrophinopathy, and retinitis pigmentosa, with lead programs OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, alongside six additional AAV candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK mutations. The company also markets Phentolamine Ophthalmic Solution 0.75%, an FDA-approved small-molecule therapy for pharmacologically induced mydriasis with additional potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery. OPGx-LCA

Price history not yet available for IRD.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar